https://eugs.bitblox.eu
Validation of Rates of Mean Deviation Change as Clinically Relevant End Points for Glaucoma Progression
May 31, 2023

Validation of Rates of Mean Deviation Change as Clinically Relevant End Points for Glaucoma Progression

Author(s): Felipe A Medeiros (1), Alessandro A Jammal (2)

1 Vision, Imaging and Performance Laboratory, Duke Eye Center, Duke University, Durham, North Carolina; Department of Electrical and Computer Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina; Department of Biostatistics and Bioinformatics, Duke University School Medicine, Durham, North Carolina. Electronic address: felipe.medeiros@duke.edu. 2 Vision, Imaging and Performance Laboratory, Duke Eye Center, Duke University, Durham, North Carolina.

PURPOSE: To investigate whether rates of standard automated perimetry (SAP) mean deviation (MD) over an initial 2-year follow-up period were predictive of events of visual field progression over an extended follow-up.

DESIGN: Longitudinal, prospective, observational study.

PARTICIPANTS: Two hundred forty-six eyes of 168 patients with glaucoma followed up every 6 months for up to 5 years.

METHODS: Patients were required to have a minimum of 5 reliable SAP tests during the first 2 years of follow-up. Events of progression were evaluated using 2 methods: Guided Progression Analysis (GPA; Carl Zeiss Meditec, Inc) and a United States Food and Drug Administration (FDA)-suggested end point. The date of the first test showing progression after the first 2 years was considered to be the event date. Rates of change in SAP MD were calculated for the first 2 years of follow-up, and joint longitudinal survival models were used to assess the risk of faster initial MD loss for subsequent progression based on each event analysis.

MAIN OUTCOME MEASURE: Risk of having an event of progression based on initial rates of SAP MD change.

RESULTS: Fifty-six eyes (22.8%) showed an event of progression by the GPA and 51 eyes (20.7%) did so by the FDA end point. Each 0.1-dB/year faster rate of SAP MD loss in the first 2 years was associated with a 26% increase in risk of a GPA progression end point developing (R2 = 76%) and 32% risk of an FDA-based end point developing (R2 = 83%). A reduction of 30% in the rate of MD change in the first 2 years was associated with a 20% reduction in the cumulative probability of a progression event developing over 5 years of follow-up.

CONCLUSIONS: Rates of SAP MD change for eyes with glaucoma calculated over the initial 2 years of follow-up were strongly predictive of events of progression over subsequent follow-up. Our findings give support for the use of slopes of MD change as suitable end points of progression in clinical trials.

Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. Ophthalmology. 2023 May;130(5):469-477. doi: 10.1016/j.ophtha.2022.12.025. Epub 2022 Dec 24.

PMID: 36574847 DOI: 10.1016/j.ophtha.2022.12.025

Keywords: Clinical trial end point; Glaucoma; Mean deviation; Perimetry, Progression


Tip of the Month manager: Anthony Khawaja
Tip of the Month editorial board: Francisco Goni, Karl Mercieca, Humma Shahid
Tip of the Month editors in chief: Manuele Michelessi, Francesco Oddone